Suppr超能文献

COVID-19 疫苗的早期批准:利弊。

Early approval of COVID-19 vaccines: Pros and cons.

机构信息

Department of Microbiology, Noakhali Science and Technology University, Noakhali, Bangladesh.

Division of Virology, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan.

出版信息

Hum Vaccin Immunother. 2021 Oct 3;17(10):3288-3296. doi: 10.1080/21645515.2021.1944742. Epub 2021 Jul 20.

Abstract

The development of safe and effective vaccines has been an overriding priority for controlling the 2019-coronavirus disease (COVID-19) pandemic. From the onset, COVID-19 has caused high mortality and economic losses and yet has also offered an opportunity to advance novel therapeutics such as DNA and mRNA vaccines. Although it is hoped that the swift acceptance of such vaccines will prevent loss of life, rejuvenate economies and restore normal life, there could also be significant pitfalls. This perspective provides an overview of future directions and challenges in advancing promising vaccine platforms to widespread therapeutic use.

摘要

开发安全有效的疫苗一直是控制 2019 年冠状病毒病(COVID-19)大流行的重中之重。从一开始,COVID-19 就导致了高死亡率和经济损失,但也为推进新型疗法(如 DNA 和 mRNA 疫苗)提供了机会。尽管人们希望这些疫苗能够迅速被接受,从而防止生命损失、重振经济并恢复正常生活,但也可能存在重大隐患。本观点概述了推进有前途的疫苗平台广泛应用于治疗所面临的未来方向和挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/996c/8437465/655c9f290763/KHVI_A_1944742_F0001_OC.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验